倍他司汀联合磷酸川芎嗪治疗脑梗死伴眩晕患者有效性及安全性分析  

Analysis of the Efficacy and Safety of Betahistine Combined with Ligustrazine Phosphate in Patients with Cerebral Infarction and Dizziness

作　　者：张亚敏 ZHANG Yamin(Department of Internal Medicine,Luoyang Petrochemical Hospital,Luoyang Henan 471012,China)

机构地区：[1]洛阳石化医院内科,河南洛阳471012

出　　处：《临床研究》2025年第1期69-72,共4页Clinical Research

摘　　要：目的探究脑梗死伴眩晕患者接受倍他司汀联合磷酸川芎嗪治疗的效果。方法选择洛阳石化医院2022年1月至2024年1月收治的72例脑梗死患者作为本研究对象,根据随机数字表法分为对照组(36例,倍他司汀治疗)与研究组(36例,倍他司汀联合磷酸川芎嗪治疗),对比两组神经缺损情况、日常生活能力、治疗效果、血液流变学指标与不良反应。结果治疗后,两组美国国立卫生研究院卒中量表(NIHSS)评分均下降,日常生活活动能力(ADL)评分均升高,且研究组NIHSS评分低于对照组,ADL评分高于对照组,差异均有统计学意义(P<0.05)。研究组治疗有效率(97.22%)高于对照组(83.33%),差异具有统计学意义(P<0.05)。治疗后,两组血液流变学指标水平均降低,且研究组低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论以眩晕为主诉的脑梗死患者接受倍他司汀与磷酸川芎嗪治疗后,其神经功能、日常生活能力与治疗效果均得到有效提升,血液流变学指标得到改善,安全性较好,值得临床借鉴。Objective To investigate the effects of betahistine combined with ligustrazine phosphate in patients with cerebral infarction accompanied by dizziness.Methods A total of 72 cerebral infarction patients admitted to Luoyang Petrochemical Hospital from January 2022 to January 2024 were selected for this study.They were randomly divided into a control group(36 cases,treated with betahistine)and a study group(36 cases,treated with betahistine combined with ligustrazine phosphate).The neurological deficits,activities of daily living,treatment effects,hemorheological indices,and adverse reactions of the two groups were compared.Results After treatment,both groups showed a decrease in the National Institutes of Health Stroke Scale(NIHSS)scores and an increase in activities of daily living(ADL)scores.The NIHSS score in the study group was significantly lower than that of the control group,while the ADL score was significantly higher in the study group,with statistically significant differences(P<0.05).The effective treatment rate in the study group(97.22%)was higher than that in the control group(83.33%),with a statistically significant difference(P<0.05).After treatment,the hemorheological indices in both groups decreased,and these indices were significantly lower in the study group compared to the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Patients with cerebral infarction and dizziness who received treatment with betahistine and ligustrazine phosphate showed significant improvements in neurological function,daily living activities,and treatment efficacy,as well as improvements in hemorheological indices.The safety profile was good,suggesting that this treatment regimen is worthy of clinical consideration.

关 键 词：脑梗死 倍他司汀 磷酸川芎嗪 神经功能 血液流变学 

分 类 号：R742[医药卫生—神经病学与精神病学]